The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

John F Tisdale - One of the best experts on this subject based on the ideXlab platform.

  • allogeneic hematopoietic Stem Cell Transplantation for sickle Cell disease
    The New England Journal of Medicine, 2009
    Co-Authors: Matthew M Hsieh, Elizabeth M Kang, Courtney D Fitzhugh, Beth M Link, Charles D Bolan, Roger Kurlander, Richard Childs, Griffin P Rodgers, Jonathan D Powell, John F Tisdale
    Abstract:

    Background Myeloablative allogeneic hematopoietic Stem-Cell Transplantation is curative in children with sickle Cell disease, but in adults the procedure is unduly toxic. Graft rejection and graft-versus-host disease (GVHD) are additional barriers to its success. We performed nonmyeloablative Stem-Cell Transplantation in adults with sickle Cell disease. Methods Ten adults (age range, 16 to 45 years) with severe sickle Cell disease underwent nonmyeloablative Transplantation with CD34+ peripheral-blood Stem Cells, mobilized by granulocyte colony-stimulating factor (G-CSF), which were obtained from HLA-matched siblings. The patients received 300 cGy of total-body irradiation plus alemtuzumab before Transplantation, and sirolimus was administered afterward. Results All 10 patients were alive at a median follow-up of 30 months after Transplantation (range, 15 to 54). Nine patients had long-term, stable donor lymphohematopoietic engraftment at levels that sufficed to reverse the sickle Cell disease phenotype. M...

Takamichi Hattori - One of the best experts on this subject based on the ideXlab platform.

  • autologous peripheral blood Stem Cell Transplantation for poems syndrome
    Neurology, 2006
    Co-Authors: Satoshi Kuwabara, Chiaki Nakaseko, Sonoko Misawa, Kazuaki Kanai, Yuriko Kikkawa, Motoi Nishimura, Ryuko Cho, Takamichi Hattori
    Abstract:

    Polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes syndrome is a rare multisyStem disorder. Overproduction of vascular endothelial growth factor (VEGF) by plasmocytoma could be responsible for the symptoms. The authors treated four patients with high-dose chemotherapy and autologous peripheral blood Stem Cell Transplantation. Within 6 months, symptoms associated with rapid normalization of serum VEGF levels improved.

Matthew M Hsieh - One of the best experts on this subject based on the ideXlab platform.

  • allogeneic hematopoietic Stem Cell Transplantation for sickle Cell disease
    The New England Journal of Medicine, 2009
    Co-Authors: Matthew M Hsieh, Elizabeth M Kang, Courtney D Fitzhugh, Beth M Link, Charles D Bolan, Roger Kurlander, Richard Childs, Griffin P Rodgers, Jonathan D Powell, John F Tisdale
    Abstract:

    Background Myeloablative allogeneic hematopoietic Stem-Cell Transplantation is curative in children with sickle Cell disease, but in adults the procedure is unduly toxic. Graft rejection and graft-versus-host disease (GVHD) are additional barriers to its success. We performed nonmyeloablative Stem-Cell Transplantation in adults with sickle Cell disease. Methods Ten adults (age range, 16 to 45 years) with severe sickle Cell disease underwent nonmyeloablative Transplantation with CD34+ peripheral-blood Stem Cells, mobilized by granulocyte colony-stimulating factor (G-CSF), which were obtained from HLA-matched siblings. The patients received 300 cGy of total-body irradiation plus alemtuzumab before Transplantation, and sirolimus was administered afterward. Results All 10 patients were alive at a median follow-up of 30 months after Transplantation (range, 15 to 54). Nine patients had long-term, stable donor lymphohematopoietic engraftment at levels that sufficed to reverse the sickle Cell disease phenotype. M...

A Zubizarreta - One of the best experts on this subject based on the ideXlab platform.

José Ignacio Lorenzo - One of the best experts on this subject based on the ideXlab platform.

  • Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic Stem Cell Transplantation
    Annals of Hematology, 2018
    Co-Authors: Pilar Solves, Jaime Sanz, Carmen Freiria, Marta Santiago, Ana Villalba, Inés Gómez, Pau Montesinos, Juan Montoro, Jose Luis Piñana, José Ignacio Lorenzo
    Abstract:

    Hematopoietic Stem Cell Transplantation has been considered a risk factor for development of platelet transfusion refractoriness. The objective of this study was to assess the platelet transfusion refractoriness rate in patients undergoing allogeneic hematopoietic Stem Cell Transplantation from different sources. We retrospectively reviewed the charts and transfusion records of patients who underwent allogeneic Stem Cell Transplantation at our institution between 2013 and 2015. The evaluation of post-transfusion platelet count was assessed for each transfusion given, from day of progenitor infusion to day 30 after Transplantation. Of 167 patients included in this study, 101 received peripheral blood Stem Cell Transplantation (PBSCT) and 66 received umbilical cord blood Transplantation (UCBT). Overall, the percentage of platelet transfusions with a 14-h CCI lower than 5000 was 59.3%, being these data significantly higher for UCBT (67.6%) than for PBSCT (31.0%). Seventy-eight percent of patients underwent UCBT become refractory, while 38.6% of patients who received PBSCT were refractory. Factors associated to platelet refractoriness were lower CD34+ Cell dose infused, higher number of antibiotics used, presence of anti-HLA I antibodies, and reduced-intensity conditioning regimen. Platelet refractoriness is a frequent and complex adverse event and remains a therapeutic challenge in the management of patients undergoing HSCT. There is a higher rate of platelet refractoriness in patients who received UCBT as compared to patients who received PBSCT.